Skip to main content
. 2016 Nov 28;20(5):162–167.

Figure 2.

Figure 2.

Changes in serum creatinine level (mg/dL) from baseline (left) and from week 4 (right) in studies comparing treatment with elvitegravir/cobicistat/emtricitabine/tenofovir (elvitegravir-based group) with efavirenz/emtricitabine/tenofovir (efavirenz-based group) or atazanavir/ritonavir plus tenofovir/emtricitabine (atazanavir-based group). Adapted with permisssion from Benson et al.8